Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adults with histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction that is inoperable, locally advanced or metastatic and not amenable to curative therapy
Adequate hematologic, liver, coagulation and kidney function
Eastern Cooperative Oncology Group (ECOG) ≤ 1
Evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1
You may not be if
Previous chemotherapy for locally advanced or metastatic gastric cancer.
Human Epidermal Growth Factor Receptor 2 (HER2)-positive gastric cancer
HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV) infection
Pregnant or breast feeding women
Individuals with known or suspected central nervous system metastases or individuals requiring chronic daily treatment with oral corticosteroids
Grade ≥ 2 peripheral neuropathy
Clareo Health | Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
